China Medical Device Registration (NMPA): Class I, II, III and Clinical Requirements for Foreign Manufacturers
Selling a medical device into China means getting it registered or filed with the NMPA, not just clearing customs. How the Class I, II and III system works, what a foreign manufacturer's Chinese agent must do, and the clinical-evaluation and quality-system requirements that decide whether you can sell.

A medical device is the one category of import where customs clearance is the easy part. Before a foreign manufacturer can legally place a device on the Chinese market, the product must be filed or registered with the National Medical Products Administration (NMPA) — or, for lower-risk devices, with a provincial counterpart — and the manufacturer must appoint a Chinese agent who answers to the regulator. The whole system runs on a three-tier risk classification, and getting the class wrong is the most expensive mistake an importer can make.
The legal frame: Order No. 739
The governing rules sit in the Regulations on the Supervision and Administration of Medical Devices (State Council Order No. 739, effective 1 June 2021), together with a large body of NMPA implementing rules, classification catalogues and guidance documents. The regulations confirm the three-class structure, the registration and filing routes, the clinical-evaluation requirement and the obligations of the foreign manufacturer's domestic responsible agent. As with most China product regimes, the catalogue and specific requirements shift over time, so the operative detail should always be checked against the current NMPA rules.
Class I, II and III: the risk ladder
- Class I — low-risk devices. Filing (备案), not registration. Handled at the provincial level. Fastest and lightest route.
- Class II — moderate-risk devices. Registration (注册) with the provincial medical products administration. The registration certificate is valid for five years.
- Class III — high-risk devices, including most implants, life-supporting devices and certain IVDs. Registration with the NMPA at the national level. The heaviest evidence burden and the longest timeline.
The class is set by the Medical Device Classification Catalogue, not by the manufacturer's own view of risk. A device that looks "low risk" can sit in Class II or III because of its intended use and the body part it touches. The catalogue is adjusted from time to time — in January 2026 the NMPA reclassified a batch of products, and some radio-frequency aesthetic devices moved into Class III from April 2026 — so confirm the class against the current version, not an old one. Classification is the decision the route, the fees, the timeline and the clinical evidence all follow from.
The domestic responsible agent
An overseas manufacturer cannot file or register directly. It must appoint a domestic responsible agent (境内责任人) established in China, who files the registration or filing application, holds the communication with the NMPA or provincial authority, and takes responsibility for the product's post-market obligations — adverse-event reporting, recalls and quality incidents. The agent's name appears on the registration certificate, so the choice of agent is a governance decision, not a paperwork detail. A weak or under-capitalised agent leaves the manufacturer exposed to enforcement it cannot control.
Clinical evaluation and the quality system
Class II and III devices generally require a clinical evaluation. This does not automatically mean a fresh Chinese clinical trial: the manufacturer can support the application with clinical data from abroad, with published literature, or with a clinical trial, depending on the device and whether it is covered by an exemption catalogue. The higher the risk and the less the device resembles an already-approved predicate, the more likely the NMPA will require China-specific clinical evidence.
Alongside the clinical file, the manufacturer must satisfy a quality-system requirement aligned with the medical-device QMS rules — in practice, a system consistent with ISO 13485 and Chinese GMP for medical devices. The NMPA can, and does, inspect overseas manufacturing sites. A registration certificate is not a promise that the site will pass inspection later.
A practical sequence for a foreign manufacturer
- Confirm the classification against the current NMPA catalogue.
- Appoint a domestic responsible agent and put the agency terms in writing.
- Assemble the technical file — standards, testing reports, labels and instructions in Chinese, and the clinical-evaluation dossier.
- Confirm the quality-system evidence and be ready for a site inspection.
- File or register, then maintain the certificate and post-market obligations through the agent.
Classification is the decision everything else hangs on. Confirm it early and in writing, because re-filing a Class II device as Class III — or discovering at the end of an import program that your product needed registration rather than filing — is the costliest error in the category. This article is general information, not regulatory or legal advice; check the current NMPA catalogue and rules for your specific device.
China medical-device compliance is a registration exercise before it is an import exercise. Get the class right, back the clinical file properly, choose a responsible agent you can hold accountable, and the rest is execution rather than surprise.


